neocryptolepine-thiazolidinedione

Neocryptolepine-thiazolidinedione is a *novel hybrid small molecule* combining a neocryptolepine scaffold (an indoloquinoline alkaloid with known antidiabetic and anti-inflammatory activity) and a thiazolidinedione moiety (a chemical group classically used in oral antidiabetic drugs). It was synthesized and characterized as a nitrogen-containing heterocyclic compound and studied preclinically for the treatment of **type 2 diabetes mellitus**. In an obesity-induced zebrafish model, NC-TZD demonstrated significant antihyperglycemic and antihyperlipidemic effects, restoring glucose, triglyceride, insulin, and inflammatory gene expression (notably nuclear factor kappa beta, *nfκβ*) to normal levels[1][3][7]. Molecular modeling suggests interaction with *PPAR-α* and peroxisomal acyl-CoA oxidase 1 (ACOX1)[3]. In silico analysis indicates promising oral bioavailability and pharmacokinetics[3]. Its mechanism is believed to involve insulin sensitization and lipid metabolism modulation, possibly through PPAR pathway agonism[3].

Other names

neocryptolepine-thiazolidinedioneNC-TZDNCL-TZD